Key result
Impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) was associated with significantly higher all-cause mortality (HR 3.69; 95% CI 1.31-10.1; P=0.011).
Why the study?
Right ventricular-to-pulmonary artery coupling is associated with outcomes in mitral regurgitation treated by transcatheter approaches, but its role in patients undergoing mitral valve surgery needed evaluation.
Does impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) predict all-cause mortality and length of stay in patients with mitral regurgitation undergoing mitral valve surgery?
Cohort (n=142)
Does impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) predict all-cause mortality and length of stay in patients with mitral regurgitation undergoing mitral valve surgery?
Hazard Ratio: 3.69 (95% CI 1.31–10.1)
Absolute Event Rate: 37% vs 8%
p-value: p=0.011
Impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) is a significant predictor of long-term mortality and prolonged hospital stay in patients undergoing mitral valve surgery for mitral regurgitation.
May support preoperative risk stratification in mitral regurgitation surgery; leaves open need for prospective validation before practice change.
OBJECTIVES: Right ventricular-to-pulmonary artery coupling has been associated with outcomes in mitral regurgitation treated by transcatheter approaches. We evaluated right ventricular-to-pulmonary artery coupling as a predictor of survival and postoperative length of hospital stay (LOS) in patients with mitral regurgitation undergoing mitral valve surgery. METHODS: In this retrospective analysis (median follow-up: 5.8 years), right ventricular-to-pulmonary artery coupling was quantified as the ratio of tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) using transthoracic echocardiography. Receiver operating characteristic curve analysis was used to determine the optimum cut-point of TAPSE/PASP to predict all-cause mortality, and the study population was dichotomized according to this value. The primary end point was all-cause mortality. A secondary end point of LOS was also assessed. RESULTS: Out of 142 patients (median age: 67, female: 49%), 35 showed impaired coupling at baseline (TAPSE/PASP ≤0.35). Patients with TAPSE/PASP ≤0.35 had higher absolute mortality (37% vs 8%, P < 0.001) and longer LOS (7 days vs 9 days, P = 0.04). Kaplan-Meier analysis revealed lower survival in patients with TAPSE/PASP ≤0.35 (log-rank: P < 0.0001). In multivariable Cox regression, TAPSE/PASP ≤0.35 was the most significant predictor of all-cause mortality (hazard ratio: 3.69, 95% confidence interval 1.31-10.1, P = 0.011), alongside chronic obstructive pulmonary disease and estimated glomerular filtration rate. TAPSE/PASP ≤0.35 was associated with significantly increased LOS (β: 4.6, 95% confidence interval 0.66-8.5, P = 0.022) alongside left ventricular ejection fraction, mitral valve replacement and urgent operation. CONCLUSIONS: In mitral regurgitation patients undergoing mitral valve surgery, TAPSE/PASP ≤0.35 is associated with increased mortality and LOS. Further validation is indicated in larger, prospective cohorts.
No takes yet. Share an insight, caveat, or question.
Chehab et al. (2024) conducted a cohort in Mitral regurgitation (n=142). Impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) vs. Normal coupling (TAPSE/PASP >0.35) was evaluated on All-cause mortality (HR 3.69, 95% CI 1.31-10.1, p=0.011). Impaired right ventricular-to-pulmonary artery coupling (TAPSE/PASP ≤0.35) was associated with significantly higher all-cause mortality (HR 3.69; 95% CI 1.31-10.1; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: